EGFR and neoplasm: SOX2 suppression by RNAi or abrogation of EGFR, Src, or Akt signaling through EGFR tyrosine kinase inhibitors Gefitinib, Erlotinib, or BIBW2992 or Src inhibitor Dasatinib could result in curbing stem-like properties and regrowth of tumor.